Scientists say they’ve zeroed in on a cause of Alzheimer’s
By
Alicia Lasek
Dec 03, 2021
Researchers from the University of California, Riverside say they have uncovered a reason why some people with plaques and tangles in their brains do not develop Alzheimer’s disease.
Dementia signs, symptoms may be different for Latinos, researchers say
By
Alicia Lasek
May 27, 2021
Cultural practices and disease processes may explain why Latino adults with dementia experience faster functional decline and higher rates of depression and anxiety, investigators say.
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
COVID-19 patients face higher risk of neurodegenerative disorders: study
By
Alicia Lasek (f3)
Jul 01, 2022
People who test positive for COVID-19 are at an increased risk of Alzheimer’s disease, Parkinson’s disease and ischemic stroke, a large new study finds.
Most women unaware of their Alzheimer’s risk, Cleveland Clinic survey finds
By
Alicia Lasek (f3)
Jun 30, 2022
Fully 82% of U.S. women are unaware of their relatively high odds of developing Alzheimer’s disease. And most have not addressed key risk factors with a healthcare provider.
Medicare costs could rise by $5B annually with expanded Alzheimer’s drug coverage: study
By
Alicia Lasek
May 12, 2023
Medicare costs could rise by $2 to $5 billion a year if CMS expands its coverage for newly approved Alzheimer’s disease drug Leqembi (lecanemab), investigators say.
Hurricanes hastened the deaths of adults with dementia, study finds
By
Alicia Lasek
Mar 08, 2023
People with Alzheimer’s and related dementias (ADRD) had higher mortality rates in U.S. counties that had recently experienced a hurricane disaster, investigators report.
Brooks-LaSure: Medicare poised to re-evaluate coverage of new Alzheimer’s drugs
By
Alicia Lasek
Dec 12, 2022
In a Milken Institute summit session, the CMS administrator said that Medicare’s door is open to evaluating new data on emerging Alzheimer’s drug candidates.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
Vascular risk factors raise odds of Alzheimer’s disease in Blacks, Hispanics: study
By
Alicia Lasek
Jan 05, 2023
Vascular risk helps to explain the outsized odds of Alzheimer’s faced by African Americans and Hispanics in the United States, a new study has found.